These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
413 related items for PubMed ID: 25124472
1. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for malignant peritoneal mesothelioma: a systematic review and meta-analysis. Helm JH, Miura JT, Glenn JA, Marcus RK, Larrieux G, Jayakrishnan TT, Donahue AE, Gamblin TC, Turaga KK, Johnston FM. Ann Surg Oncol; 2015 May; 22(5):1686-93. PubMed ID: 25124472 [Abstract] [Full Text] [Related]
2. Iterative cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent or progressive diffuse malignant peritoneal mesothelioma: clinicopathologic characteristics and survival outcome. Ihemelandu C, Bijelic L, Sugarbaker PH. Ann Surg Oncol; 2015 May; 22(5):1680-5. PubMed ID: 25120250 [Abstract] [Full Text] [Related]
3. Institutional learning curve of cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion for peritoneal malignancies. Polanco PM, Ding Y, Knox JM, Ramalingam L, Jones H, Hogg ME, Zureikat AH, Holtzman MP, Pingpank J, Ahrendt S, Zeh HJ, Bartlett DL, Choudry HA. Ann Surg Oncol; 2015 May; 22(5):1673-9. PubMed ID: 25377640 [Abstract] [Full Text] [Related]
4. Conversion to Complete Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Malignant Peritoneal Mesothelioma After Bidirectional Chemotherapy. Le Roy F, Gelli M, Hollebecque A, Honoré C, Boige V, Dartigues P, Benhaim L, Malka D, Ducreux M, Elias D, Goéré D. Ann Surg Oncol; 2017 Nov; 24(12):3640-3646. PubMed ID: 28849389 [Abstract] [Full Text] [Related]
5. The Role of Ki-67 and Pre-cytoreduction Parameters in Selecting Diffuse Malignant Peritoneal Mesothelioma (DMPM) Patients for Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC). Kusamura S, Torres Mesa PA, Cabras A, Baratti D, Deraco M. Ann Surg Oncol; 2016 May; 23(5):1468-73. PubMed ID: 26572754 [Abstract] [Full Text] [Related]
6. Malignant peritoneal mesothelioma: prognostic factors and oncologic outcome analysis. Magge D, Zenati MS, Austin F, Mavanur A, Sathaiah M, Ramalingam L, Jones H, Zureikat AH, Holtzman M, Ahrendt S, Pingpank J, Zeh HJ, Bartlett DL, Choudry HA. Ann Surg Oncol; 2014 Apr; 21(4):1159-65. PubMed ID: 24322529 [Abstract] [Full Text] [Related]
7. Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial. de Boer NL, van Kooten JP, Burger JWA, Verhoef C, Aerts JGJV, Madsen EVE. BMJ Open; 2019 May 14; 9(5):e026779. PubMed ID: 31092657 [Abstract] [Full Text] [Related]
8. Malignant Peritoneal Mesothelioma: National Practice Patterns, Outcomes, and Predictors of Survival. Verma V, Sleightholm RL, Rusthoven CG, Koshy M, Sher DJ, Grover S, Simone CB. Ann Surg Oncol; 2018 Jul 14; 25(7):2018-2026. PubMed ID: 29721724 [Abstract] [Full Text] [Related]
9. Repeat cytoreductive surgery and heated intraperitoneal chemotherapy may offer survival benefit for intraperitoneal mesothelioma: a single institution experience. Wong J, Koch AL, Deneve JL, Fulp W, Tanvetyanon T, Dessureault S. Ann Surg Oncol; 2014 May 14; 21(5):1480-6. PubMed ID: 24158467 [Abstract] [Full Text] [Related]
10. Early recurrence after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). Tan GHC, Chia CS, Tan SH, Soo KC, Teo MCC. Int J Clin Oncol; 2018 Oct 14; 23(5):989-998. PubMed ID: 29869757 [Abstract] [Full Text] [Related]
11. Is Cytoreductive Surgery with Hyperthermic Intraperitoneal Chemotherapy Justified for Biphasic Variants of Peritoneal Mesothelioma? Outcomes from the Peritoneal Surface Oncology Group International Registry. Votanopoulos KI, Sugarbaker P, Deraco M, Morris D, Glehen O, Elias D, De Simone M, Robella M, Heyd B, Kusamura S, Baratti D, Chouliaras K, Russell G, Shen P, Levine EA, RENAPE Working Group. Ann Surg Oncol; 2018 Mar 14; 25(3):667-673. PubMed ID: 29260418 [Abstract] [Full Text] [Related]
12. [Meta analysis of whether cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy can improve survival in patients with colorectal cancer peritoneal metastasis]. Liu D, Wang H, Yuan ZX, Chen WW, Wu ZJ, Liu XX, Luo J, Chu LL, Li Y, Cai J. Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar 25; 24(3):256-263. PubMed ID: 34645170 [Abstract] [Full Text] [Related]
13. Impact of Combination Chemotherapy in Peritoneal Mesothelioma Hyperthermic Intraperitoneal Chemotherapy (HIPEC): The RENAPE Study. Malgras B, Gayat E, Aoun O, Lo Dico R, Eveno C, Pautrat K, Delhorme JB, Passot G, Marchal F, Sgarbura O, Ferron G, Goéré D, Andre T, Pocard M, RENAPE Network. Ann Surg Oncol; 2018 Oct 25; 25(11):3271-3279. PubMed ID: 29978366 [Abstract] [Full Text] [Related]
14. What made hyperthermic intraperitoneal chemotherapy an effective curative treatment for peritoneal surface malignancy: A 25-year experience with 1,125 procedures. Passot G, Vaudoyer D, Villeneuve L, Kepenekian V, Beaujard AC, Bakrin N, Cotte E, Gilly FN, Glehen O. J Surg Oncol; 2016 Jun 25; 113(7):796-803. PubMed ID: 27110915 [Abstract] [Full Text] [Related]
15. Repeat cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for recurrent diffuse malignant peritoneal mesothelioma. Huang Y, Alzahrani NA, Liauw W, Morris DL. Eur J Surg Oncol; 2015 Oct 25; 41(10):1373-8. PubMed ID: 26227745 [Abstract] [Full Text] [Related]
16. Treating peritoneal mesothelioma with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. A case series and review of the literature. Stamou K, Tsamis D, Pallas N, Samanta E, Courcoutsakis N, Prassopoulos P, Tentes AA. Int J Hyperthermia; 2015 Oct 25; 31(8):850-6. PubMed ID: 26382910 [Abstract] [Full Text] [Related]
17. Multicystic and diffuse malignant peritoneal mesothelioma in children. Vermersch S, Arnaud A, Orbach D, Andre N, Berger C, Kepenekian V, Brigand C, Fresneau B, Poli-Merol ML, Habougit C, Varlet F, Scalabre A. Pediatr Blood Cancer; 2020 Jun 25; 67(6):e28286. PubMed ID: 32277799 [Abstract] [Full Text] [Related]
18. Outcomes of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Peritoneal Mesothelioma: Experience of a Peritoneal Surface Malignancy Center. Aydin N, Sardi A, Milovanov V, Nieroda C, Sittig M, Nunez MF, Jimenez W, Gushchin V. Am Surg; 2015 Dec 25; 81(12):1253-9. PubMed ID: 26736164 [Abstract] [Full Text] [Related]
19. Preoperative Thrombocytosis Predicts Shortened Survival in Patients with Malignant Peritoneal Mesothelioma Undergoing Operative Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy. Li YC, Khashab T, Terhune J, Eckert RL, Hanna N, Burke A, Richard Alexander H. Ann Surg Oncol; 2017 Aug 25; 24(8):2259-2265. PubMed ID: 28324285 [Abstract] [Full Text] [Related]
20. Effect of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy on Quality of Life in Patients with Peritoneal Mesothelioma. Ali YM, Sweeney J, Shen P, Votanopoulos KI, McQuellon R, Duckworth K, Perry KC, Russell G, Levine EA. Ann Surg Oncol; 2020 Jan 25; 27(1):117-123. PubMed ID: 31069554 [Abstract] [Full Text] [Related] Page: [Next] [New Search]